Advertisement
News
Advertisement

Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller

Thu, 06/02/2011 - 3:33am
Bio-Medicine.Org

PRINCETON, N.J., June 2, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it recently appointed Joseph Warusz as its new Vice President of Administration and Controller. In this role, Mr. Warusz will oversee the Accounting, Human Resources, and Administrative functions, as well as serve as the Company's Principal Accounting Officer for SEC reporting purposes.

Mr. Warusz comes to Soligenix with more than 28 years of financial management experience in public and private life science companies as well as large pharma. Prior to joining Soligenix, he held senior financial positions with Amicus Therapeutics, Inc., Orchid Cellmark, Inc., and NexMed, Inc., as well as consulting assignments at Ardea BioSciences, Inc., and NovaDel Pharma, Inc., all R&D-focused companies in the biotechnology and specialty pharmaceuticals arenas.  Prior to 1998, Mr. Warusz also held management positions in financial analysis, accounting, reporting and auditing at Bristol-Myers Squibb and Peat Marwick Main & Company. He received his BS in accounting and MBA in finance at Drexel University and was a Certified Public Accountant previously licensed in the State of Pennsylvania.

"I am very excited to be joining Soligenix at this point in its development and I look forward to contributing to the company's continued growth in 2011 and beyond," stated Mr. Warusz.

"We are very pleased to welcome Joseph to the Soligenix team," said Evan Myrianthopoulos, Chief Financial Officer of Soligenix. "His experience with development stage and commercial biotech and pharmaceutical companies will serve us well as we diligently work to complete our confirmatory Phase 3 clinical trial of orBec® in the treatment of acute GI GVHD."

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company developing products to treat life-threatening side effe

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading